Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMRX |
---|---|---|
09:32 ET | 13960 | 2.05 |
09:33 ET | 38257 | 2.06 |
09:39 ET | 9353 | 2.07 |
09:42 ET | 300 | 2.07 |
09:44 ET | 21094 | 2.1 |
09:46 ET | 11157 | 2.15 |
09:48 ET | 1378 | 2.15 |
09:50 ET | 12536 | 2.1107 |
09:51 ET | 15083 | 2.1196 |
09:55 ET | 6360 | 2.1 |
09:57 ET | 4300 | 2.1 |
10:00 ET | 9890 | 2.0601 |
10:02 ET | 5300 | 2.04 |
10:08 ET | 2774 | 2.0693 |
10:09 ET | 2140 | 2.0908 |
10:13 ET | 4575 | 2.12 |
10:15 ET | 450 | 2.1 |
10:18 ET | 1189 | 2.1235 |
10:22 ET | 300 | 2.124 |
10:24 ET | 681 | 2.1262 |
10:26 ET | 5499 | 2.13 |
10:29 ET | 1531 | 2.11 |
10:33 ET | 2770 | 2.1 |
10:36 ET | 400 | 2.1 |
10:38 ET | 5150 | 2.0838 |
10:45 ET | 3214 | 2.11 |
10:49 ET | 500 | 2.1132 |
10:54 ET | 1750 | 2.1309 |
10:58 ET | 310 | 2.13 |
11:00 ET | 3094 | 2.14 |
11:02 ET | 450 | 2.1452 |
11:03 ET | 5000 | 2.14 |
11:07 ET | 1800 | 2.148 |
11:09 ET | 3331 | 2.16 |
11:12 ET | 4708 | 2.1536 |
11:14 ET | 6879 | 2.1693 |
11:16 ET | 31431 | 2.21 |
11:18 ET | 20633 | 2.19 |
11:20 ET | 899 | 2.189 |
11:23 ET | 1254 | 2.17 |
11:25 ET | 1124 | 2.1698 |
11:30 ET | 200 | 2.164 |
11:38 ET | 372 | 2.1796 |
11:39 ET | 8339 | 2.17 |
11:41 ET | 1344 | 2.17 |
11:48 ET | 231 | 2.15 |
11:50 ET | 850 | 2.1595 |
11:52 ET | 2154 | 2.15 |
11:56 ET | 808 | 2.122 |
11:57 ET | 700 | 2.1391 |
11:59 ET | 100 | 2.13 |
12:01 ET | 400 | 2.14 |
12:06 ET | 234 | 2.14 |
12:08 ET | 100 | 2.13 |
12:10 ET | 300 | 2.14 |
12:14 ET | 475 | 2.13 |
12:21 ET | 2613 | 2.13 |
12:26 ET | 600 | 2.1346 |
12:30 ET | 350 | 2.13 |
12:33 ET | 100 | 2.12 |
12:39 ET | 200 | 2.13 |
12:42 ET | 2035 | 2.15 |
12:46 ET | 6376 | 2.1574 |
12:50 ET | 242 | 2.16 |
12:51 ET | 1400 | 2.15 |
01:04 ET | 250 | 2.13 |
01:15 ET | 1395 | 2.15 |
01:20 ET | 1750 | 2.1598 |
01:29 ET | 100 | 2.16 |
01:33 ET | 1839 | 2.1608 |
01:38 ET | 109 | 2.1608 |
01:45 ET | 1100 | 2.1612 |
01:54 ET | 200 | 2.1624 |
01:56 ET | 639 | 2.1775 |
02:02 ET | 2359 | 2.1898 |
02:03 ET | 600 | 2.185 |
02:05 ET | 784 | 2.19 |
02:07 ET | 100 | 2.17 |
02:09 ET | 2099 | 2.174 |
02:18 ET | 700 | 2.19 |
02:20 ET | 1700 | 2.18 |
02:25 ET | 12000 | 2.1799 |
02:27 ET | 191 | 2.185 |
02:30 ET | 6734 | 2.185 |
02:32 ET | 100 | 2.1851 |
02:34 ET | 915 | 2.179 |
02:36 ET | 20698 | 2.1899 |
02:38 ET | 45218 | 2.225 |
02:39 ET | 12300 | 2.207 |
02:41 ET | 2380 | 2.19 |
02:43 ET | 3000 | 2.18 |
02:56 ET | 625 | 2.18 |
02:57 ET | 1090 | 2.17 |
03:01 ET | 100 | 2.17 |
03:08 ET | 462 | 2.17 |
03:14 ET | 956 | 2.1601 |
03:15 ET | 154 | 2.1504 |
03:17 ET | 3990 | 2.16 |
03:21 ET | 1000 | 2.16 |
03:32 ET | 2250 | 2.159 |
03:44 ET | 300 | 2.1281 |
03:46 ET | 1800 | 2.1392 |
03:48 ET | 3840 | 2.14 |
03:50 ET | 820 | 2.15 |
03:51 ET | 583 | 2.12 |
03:53 ET | 2304 | 2.1273 |
03:55 ET | 826 | 2.12 |
03:57 ET | 6517 | 2.115 |
04:00 ET | 10775 | 2.11 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immuneering Corp | 62.6M | -1.1x | --- |
RetinalGenix Technologies Inc | 63.0M | -15.3x | --- |
X4 Pharmaceuticals Inc | 62.1M | -4.3x | --- |
Entera Bio Ltd | 59.7M | -6.2x | --- |
Allovir Inc | 65.9M | -0.7x | --- |
Bioatla Inc | 67.2M | -0.8x | --- |
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.35 |
EPS | $-1.97 |
Book Value | $3.09 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.